Mirai Bio

Mirai, founded by Flagship Pioneering in 2021, is led by experts with decades of experience driving innovation in genetic medicines. The company is a pioneer in the biotechnology industry's first open end-to-end platform capable of co-creating fully optimized genetic medicines. Mirai’s machine intelligence-based open platform utilizes proprietary data algorithms and machine intelligence to deliver drugs to any tissue and cell type, optimize drug design, and facilitate manufacturing, thereby accelerating the clinical translation of genetic medicines and helping its partners succeed. Mirai’s cutting-edge platform employs high-throughput automation and in vivo multiplexing technologies to generate vast amounts of data, powering extensive optimization cycles. The co-optimization of delivery, design, and manufacturing has the potential to increase the probability of success for any genetic medicine while reducing development time.